Shattuck Labs (STTK) Competitors $0.96 +0.07 (+7.30%) Closing price 08/22/2025 04:00 PM EasternExtended Trading$0.94 -0.02 (-2.08%) As of 08/22/2025 06:17 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock STTK vs. EPRX, KRRO, TNYA, ENGN, TIL, SXTC, CRBU, CCCC, TVGN, and SLSShould you be buying Shattuck Labs stock or one of its competitors? The main competitors of Shattuck Labs include Eupraxia Pharmaceuticals (EPRX), Korro Bio (KRRO), Tenaya Therapeutics (TNYA), enGene (ENGN), Instil Bio (TIL), China SXT Pharmaceuticals (SXTC), Caribou Biosciences (CRBU), C4 Therapeutics (CCCC), Tevogen Bio (TVGN), and SELLAS Life Sciences Group (SLS). These companies are all part of the "pharmaceutical products" industry. Shattuck Labs vs. Its Competitors Eupraxia Pharmaceuticals Korro Bio Tenaya Therapeutics enGene Instil Bio China SXT Pharmaceuticals Caribou Biosciences C4 Therapeutics Tevogen Bio SELLAS Life Sciences Group Eupraxia Pharmaceuticals (NASDAQ:EPRX) and Shattuck Labs (NASDAQ:STTK) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their valuation, earnings, media sentiment, profitability, analyst recommendations, risk, institutional ownership and dividends. Which has more risk and volatility, EPRX or STTK? Eupraxia Pharmaceuticals has a beta of 1.5, suggesting that its stock price is 50% more volatile than the S&P 500. Comparatively, Shattuck Labs has a beta of 1.63, suggesting that its stock price is 63% more volatile than the S&P 500. Do analysts rate EPRX or STTK? Eupraxia Pharmaceuticals currently has a consensus target price of $11.00, suggesting a potential upside of 108.33%. Shattuck Labs has a consensus target price of $7.00, suggesting a potential upside of 629.17%. Given Shattuck Labs' higher probable upside, analysts clearly believe Shattuck Labs is more favorable than Eupraxia Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Eupraxia Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 3.17Shattuck Labs 0 Sell rating(s) 3 Hold rating(s) 1 Buy rating(s) 2 Strong Buy rating(s) 2.83 Does the media favor EPRX or STTK? In the previous week, Eupraxia Pharmaceuticals had 2 more articles in the media than Shattuck Labs. MarketBeat recorded 12 mentions for Eupraxia Pharmaceuticals and 10 mentions for Shattuck Labs. Shattuck Labs' average media sentiment score of 0.30 beat Eupraxia Pharmaceuticals' score of -0.24 indicating that Shattuck Labs is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Eupraxia Pharmaceuticals 1 Very Positive mention(s) 3 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Shattuck Labs 0 Very Positive mention(s) 0 Positive mention(s) 7 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Which has preferable earnings & valuation, EPRX or STTK? Eupraxia Pharmaceuticals has higher earnings, but lower revenue than Shattuck Labs. Eupraxia Pharmaceuticals is trading at a lower price-to-earnings ratio than Shattuck Labs, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioEupraxia PharmaceuticalsN/AN/A-$25.50M-$0.85-6.21Shattuck Labs$3.00M15.34-$75.41M-$1.21-0.79 Is EPRX or STTK more profitable? Shattuck Labs' return on equity of -81.80% beat Eupraxia Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Eupraxia PharmaceuticalsN/A -367.73% -126.38% Shattuck Labs N/A -81.80%-71.46% Do institutionals and insiders hold more shares of EPRX or STTK? 58.7% of Shattuck Labs shares are held by institutional investors. 12.0% of Shattuck Labs shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term. SummaryShattuck Labs beats Eupraxia Pharmaceuticals on 10 of the 15 factors compared between the two stocks. Get Shattuck Labs News Delivered to You Automatically Sign up to receive the latest news and ratings for STTK and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding STTK and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart STTK vs. The Competition Export to ExcelMetricShattuck LabsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$42.86M$3.11B$5.76B$9.58BDividend YieldN/A2.23%4.41%4.10%P/E Ratio-0.7920.8831.1026.04Price / Sales15.34348.74435.03103.40Price / CashN/A43.1937.7358.48Price / Book0.818.129.536.61Net Income-$75.41M-$54.72M$3.26B$265.56M7 Day Performance-4.00%2.63%2.10%1.97%1 Month Performance17.14%2.78%2.82%-0.36%1 Year Performance-72.57%11.01%30.56%19.03% Shattuck Labs Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)STTKShattuck Labs3.5432 of 5 stars$0.96+7.3%$7.00+629.2%-70.6%$42.86M$3.00M-0.79100News CoverageEPRXEupraxia Pharmaceuticals1.9886 of 5 stars$5.30-0.4%$11.00+107.5%+103.1%$191.42MN/A-6.2429News CoverageAnalyst ForecastGap UpKRROKorro Bio1.343 of 5 stars$19.72-2.7%$86.83+340.3%-54.7%$190.26M$2.27M-2.0270TNYATenaya Therapeutics2.8325 of 5 stars$1.26+8.6%$6.25+396.0%-58.5%$189.05MN/A-1.31110High Trading VolumeENGNenGene3.3368 of 5 stars$3.72+1.1%$23.29+526.0%-28.7%$188.07MN/A-2.2531News CoverageTILInstil Bio3.3997 of 5 stars$28.85+3.6%$119.00+312.5%+115.9%$187.94MN/A-2.23410SXTCChina SXT Pharmaceuticals0.7696 of 5 stars$1.59-0.6%N/A-78.2%$185.64M$1.74M0.0090News CoveragePositive NewsShort Interest ↑Gap DownCRBUCaribou Biosciences2.8756 of 5 stars$1.87-5.6%$6.67+256.5%-11.5%$184.38M$9.99M-1.05100CCCCC4 Therapeutics1.2641 of 5 stars$2.86+16.3%$8.00+179.7%-56.9%$175.08M$35.58M-1.81150Gap UpHigh Trading VolumeTVGNTevogen Bio3.9847 of 5 stars$0.96+1.6%$10.00+937.6%+55.8%$174.39MN/A0.003News CoverageEarnings ReportSLSSELLAS Life Sciences Group2.8906 of 5 stars$1.73+6.1%$7.00+304.6%+45.8%$171.63M$1M-5.4110 Related Companies and Tools Related Companies Eupraxia Pharmaceuticals Competitors Korro Bio Competitors Tenaya Therapeutics Competitors enGene Competitors Instil Bio Competitors China SXT Pharmaceuticals Competitors Caribou Biosciences Competitors C4 Therapeutics Competitors Tevogen Bio Competitors SELLAS Life Sciences Group Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:STTK) was last updated on 8/23/2025 by MarketBeat.com Staff From Our PartnersBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Shattuck Labs, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Shattuck Labs With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access